Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Infection and Immunity

• Publication date

  1994-11-01

• Fields of study

  Biology, Medicine, Computer Science

• Identifiers
  DOI 10.1128/iai.62.11.5055-5065.1994PMID 7927788PMCID PMC303226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotoxin therapy of cancer

  2006cited by this paper
• Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner.

  1994cited by this paper
• Immunotoxin therapy of cancer.

  1993cited by this paper
• Humanized antibodies: enhancing therapeutic utility through antibody engineering.

  1993cited by this paper
• Comparative immunochemistry of two fragments from domains Ib and III of Pseudomonas aeruginosa exotoxin A

  1993cited by this paper
• The use of immunotoxins for cancer therapy.

  1993cited by this paper
• Mapping antibody binding sites on cytochrome c with synthetic peptides: Are results representative of the antigenic structure of proteins?

  1993cited by this paper
• Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.

  1992cited by this paper
• Recombinant toxins as novel therapeutic agents.

  1992cited by this paper
• Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.

  1992cited by this paper
• Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.

  1991cited by this paper
• Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin.

  1991cited by this paper
• Epitope mapping employing immobilized synthetic peptides. How specific is the reactivity of these peptides with antiserum raised against the parent protein?

  1991cited by this paper
• Protein antigenicity: a thermodynamic approach.

  1991influential reference
• Systematic fractionation of serum antibodies using multiple antigen homologous peptides as affinity ligands.

  1991cited by this paper
• Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas.

  1991cited by this paper
• Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes

  1991cited by this paper
• B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

  1991influential reference
• Epitopes on protein antigens: misconceptions and realities.

  1990cited by this paper
• Identification of functional epitopes of Pseudomonas aeruginosa exotoxin A using synthetic peptides and subclone products.

  1990cited by this paper
• On the attribution of binding energy in antigen-antibody complexes McPC 603, D1.3, and HyHEL-5.

  1989cited by this paper
• Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain.

  1988cited by this paper
• Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

  1987cited by this paper
• Redesigning nature's poisons to create anti-tumor reagents.

  1987cited by this paper
• Chemistry of antibody binding to a protein.

  1987cited by this paper
• Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin.

  1987cited by this paper
• Strategies for epitope analysis using peptide synthesis.

  1987cited by this paper
• Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.

  1986influential reference
• Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A

  1986cited by this paper
• Diphtheria toxin. Site and configuration of ADP-ribosylation of diphthamide in elongation factor 2.

  1981cited by this paper
• NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,.

  1975cited by this paper
• The interpretation of protein structures: estimation of static accessibility.

  1971cited by this paper

• Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation

  2020cites this paper
• Introduction Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies

  2017cites this paper
• Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Deimmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins

  2017cites this paper
• Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.

  2016cites this paper
• Fully human MAP‐fusion protein selectively targets and eliminates proliferating CD64+ M1 macrophages

  2016cites this paper
• Immunogenicity of therapeutic recombinant immunotoxins

  2016cites this paper
• Resistance to Immunotoxins in Cancer Therapy

  2015cites this paper
• Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins

  2015cites this paper
• Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

  2014cites this paper
• CD64-mediated specific elimination of M1-polarized macrophages : implications for therapeutic intervention in chronic inflammatory diseases

  2013cites this paper
• Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies

  2012cites this paper
• Macrophage-Targeted Therapy: CD64-Based Immunotoxins for Treatment of Chronic Inflammatory Diseases

  2012cites this paper
• Antibodies in single-chain format against tumour-associated antigens: present and future applications.

  2010cites this paper
• Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.

  2009cites this paper
• CELL-TARGETED RIBOSOME-INACTIVATING PROTEINS DERIVED FROM PROTEIN COMBINATORIAL LIBRARIES

  2008cites this paper
• PatientsImmunotoxins for the Treatment of Cancer Exotoxin (PE38) Used to Make Pseudomonas Associated with a Truncated Form of Characterization of the B Cell Epitopes

  2006cites this paper
• Immunotoxins in the treatment of hematologic malignancies.

  2006cites this paper
• Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1

  2006cites this paper
• Immunotoxins for targeted cancer therapy

  2006cites this paper
• Reducing the Immune Response to Immunotoxin

  2004cites this paper
• Peptide-Based Vaccines

  2004cites this paper
• Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules.

  2003cites this paper
• HER-2/neu vaccines.

  2003cites this paper
• Targeted toxins

  1999cites this paper
• Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

  1999cites this paper
• Protection against Exotoxin A (ETA) andPseudomonas aeruginosa Infection in Mice with ETA-Specific Antipeptide Antibodies

  1998cites this paper
• HER-2/neu oncogenic protein: issues in vaccine development.

  1998cites this paper
• Immunotoxins for targeted cancer therapy.

  1998cites this paper
• Generation of Neutralizing Antipeptide Antibodies to the Enzymatic Domain of Pseudomonas aeruginosa Exotoxin A

  1998influential citation
• Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins

  1997cites this paper
• HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

  1997cites this paper
• Treatment of advanced solid tumors with immunotoxin LMB–1: An antibody linked to Pseudomonas exotoxin

  1996cites this paper
• Immunity to Oncogenic Proteins

  1995cites this paper
• Clinical trials of targeted toxins.

  1995cites this paper